Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
| Autor: | Black, S, Wilcock, G, Zavitz, K, Hendrix, S, Swabb, E |
|---|---|
| Rok vydání: | 2016 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|